Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives $6.75 Consensus PT from Analysts

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Get Free Report) has received an average recommendation of "Moderate Buy" from the six brokerages that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $6.75.

Several analysts have recently commented on ESPR shares. JMP Securities reiterated a "market outperform" rating and set a $4.00 price objective (down previously from $7.00) on shares of Esperion Therapeutics in a report on Tuesday, February 11th. Needham & Company LLC restated a "buy" rating and issued a $6.00 target price on shares of Esperion Therapeutics in a research note on Friday, December 13th. HC Wainwright reiterated a "buy" rating and set a $16.00 price target on shares of Esperion Therapeutics in a research note on Thursday, March 20th. Cantor Fitzgerald started coverage on Esperion Therapeutics in a research note on Tuesday, December 17th. They issued an "overweight" rating and a $8.00 price objective for the company. Finally, The Goldman Sachs Group began coverage on Esperion Therapeutics in a research report on Wednesday, December 18th. They issued a "neutral" rating and a $4.00 target price on the stock.

Institutional Investors Weigh In On Esperion Therapeutics

Several hedge funds have recently bought and sold shares of ESPR. Cibc World Markets Corp acquired a new position in shares of Esperion Therapeutics in the 4th quarter valued at $39,000. SJS Investment Consulting Inc. acquired a new position in shares of Esperion Therapeutics in the fourth quarter worth about $55,000. Crestline Management LP purchased a new stake in shares of Esperion Therapeutics during the 4th quarter worth about $63,000. Foundations Investment Advisors LLC grew its position in shares of Esperion Therapeutics by 48.6% during the 4th quarter. Foundations Investment Advisors LLC now owns 30,172 shares of the biopharmaceutical company's stock valued at $66,000 after acquiring an additional 9,872 shares during the period. Finally, J.W. Cole Advisors Inc. purchased a new position in shares of Esperion Therapeutics in the 4th quarter valued at about $66,000. Hedge funds and other institutional investors own 47.39% of the company's stock.

Remove Ads

Esperion Therapeutics Stock Performance

ESPR traded down $0.07 on Friday, hitting $1.44. The company had a trading volume of 3,153,894 shares, compared to its average volume of 5,775,391. The stock has a market capitalization of $283.91 million, a price-to-earnings ratio of -2.27 and a beta of 1.04. The stock has a fifty day moving average price of $1.78 and a 200-day moving average price of $2.07. Esperion Therapeutics has a 12-month low of $1.43 and a 12-month high of $3.94.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.